A Multi-center Study to Assess the Efficacy and Safety of LX211 in Active Non-infectious Anterior Uveitis

A Double-Masked, Placebo-Controlled, Parallel-Group, Multi-Center, Dose-Ranging Study With an Optional Extension to Assess the Efficacy and Safety of LX211 as Therapy in Subjects With Active Sight Threatening, Non-infectious Anterior Uveitis

The objective of this study is to evaluate the safety and efficacy of LX211 as therapy in subjects with active non-infectious anterior uveitis

Inclusion Criteria:

• Documented history of non-infectious anterior, anterior and intermediate- or panuveitis
• Currently uncontrolled uveitis for a minimum of 2 weeks despite use of oral and/or topical corticosteroid,or subjects who are intolerant of local corticosteroid therapy due to the development of an ocular hypertensive response or subjects for whom oral corticosteroid is contraindicated.
• Grade of 2+ or higher for anterior chamber cells at time of enrollment
• Considered by the investigator to require corticosteroid-sparing therapy.
• Subjects not planning to undergo elective ocular surgery during the study

Exclusion Criteria:

• Uveitis of infectious etiology
• Presence of an ocular toxoplasmosis scar
• An immune suppression regimen that includes an alkylating agent within the previous 90 days